Immune checkpoint inhibitors in ovarian cancer: where do we stand?
PARP inhibitors
anti-angiogenic
combinations
immune checkpoint inhibitors
ovarian cancer
predictive biomarkers
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
02
2021
accepted:
29
07
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
Numerous retrospective studies have demonstrated that the density of intra-tumoral immune cell infiltration is prognostic in epithelial ovarian cancer (OC). These observations together with reports of programmed death ligand-1 (PD-L1) expression in advanced OC provided the rationale for investigating the benefit of programmed death-1 (PD1) or PD-L1 inhibition in OC. Unfortunately clinical trials to date evaluating PD1/PD-L1 inhibition in patients with relapsed OC have been disappointing. In this review we will discuss early results from single agent PD1/PD-L1 inhibitors and the strategies to enhance benefit from immune-oncology agents in OC, including proposing anti-PD-L1 in combination with other agents (cytotoxics, anti-angiogenics, poly(ADP-ribose) polymerase. (PARP) inhibitors, targeted therapies or other immunotherapies), as well as evaluating these agents earlier in the disease course, or in biomarker selected patients.
Identifiants
pubmed: 34422119
doi: 10.1177/17588359211039899
pii: 10.1177_17588359211039899
pmc: PMC8377306
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17588359211039899Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: AL: paid fees to the institution or to myself for ad boards: AZ, Clovis, MSD, MERCK serono, Ability Pharma, Biocad, Zentalis, Tesaro, GSK. Travel to congress from AZ, Roche, Clovis, Tesaro, GSK CI, PI or coInv on trials sponsored and or funded by AZ, Clovis, Ability, Roche, MSD, BMS, GSK, Agenus, AZ, Iovance.
Références
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Crit Rev Oncol Hematol. 2019 May;137:35-42
pubmed: 31014514
Oncoimmunology. 2019 Mar 16;8(5):e1581556
pubmed: 31069145
Gynecol Oncol. 2018 Nov;151(2):381-389
pubmed: 30217369
Gynecol Oncol. 2017 Oct;147(1):181-187
pubmed: 28698008
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
Tumour Biol. 2016 Mar;37(3):3949-56
pubmed: 26482613
EBioMedicine. 2019 Dec;50:203-210
pubmed: 31761620
EMBO Mol Med. 2013 Jul;5(7):1051-66
pubmed: 23666744
Cancer Immunol Res. 2014 Nov;2(11):1080-9
pubmed: 25080445
Lancet Oncol. 2016 Aug;17(8):1037-1039
pubmed: 27324281
Clin Cancer Res. 2018 Nov 15;24(22):5562-5573
pubmed: 29853601
J Clin Invest. 2016 Oct 3;126(10):3672-3679
pubmed: 27482883
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Lymphokine Cytokine Res. 1993 Dec;12(6):429-37
pubmed: 8123759
J Clin Oncol. 2006 Feb 10;24(5):762-8
pubmed: 16391298
J Clin Oncol. 2017 Jul 1;35(19):2193-2202
pubmed: 28471727
Clin Cancer Res. 2008 Dec 1;14(23):7667-73
pubmed: 19047092
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
J Clin Oncol. 2020 Sep 10;38(26):2981-2992
pubmed: 32167863
Nat Genet. 2020 Jun;52(6):582-593
pubmed: 32483290
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30895946
Cancer J Sci Am. 1996 Sep-Oct;2(5):263-72
pubmed: 9166543
Gynecol Oncol. 2020 Mar;156(3):669-675
pubmed: 31924330
J Clin Oncol. 2020 Jun 1;38(16):1814-1823
pubmed: 32275468
JAMA Oncol. 2019 Aug 1;5(8):1141-1149
pubmed: 31194228
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Ann Oncol. 2017 Mar 1;28(3):651-657
pubmed: 27864219
Nat Commun. 2020 Mar 19;11(1):1459
pubmed: 32193378
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
J Natl Cancer Inst. 2018 Jul 1;110(7):787-790
pubmed: 29365144
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Int J Mol Sci. 2019 Jun 15;20(12):
pubmed: 31208030
J Immunother Cancer. 2018 Dec 27;6(1):158
pubmed: 30587236
JAMA Oncol. 2021 Jan 1;7(1):78-85
pubmed: 33211063
Am J Cancer Res. 2019 Feb 01;9(2):212-218
pubmed: 30906623
JAMA Oncol. 2019 Dec 1;5(12):1731-1738
pubmed: 31600397
Mod Pathol. 2017 Nov;30(11):1622-1632
pubmed: 28752845
Clin Cancer Res. 2008 Jun 1;14(11):3372-9
pubmed: 18519766
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Clin Cancer Res. 2003 Apr;9(4):1517-27
pubmed: 12684428
Cancer Res. 2013 Jun 15;73(12):3591-603
pubmed: 23633484
Oncotarget. 2017 Feb 28;8(9):15621-15631
pubmed: 28152503
Cancer Immunol Immunother. 2021 Feb;70(2):519-531
pubmed: 32852603
Clin Cancer Res. 2013 Jul 1;19(13):3474-84
pubmed: 23633455
Gynecol Oncol. 2016 Nov;143(2):393-397
pubmed: 27569584
Cells. 2020 Jun 19;9(6):
pubmed: 32575483
Cancer Res. 2003 Sep 15;63(18):6076-83
pubmed: 14522938
Ann Oncol. 2019 Jul 1;30(7):1025-1028
pubmed: 31111866
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Cancer Res. 2012 Sep 1;72(17):4351-60
pubmed: 22798340
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Clin Cancer Res. 2018 Aug 1;24(15):3560-3571
pubmed: 29661778
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Clin Cancer Res. 2017 Jul 1;23(13):3371-3384
pubmed: 28003307
Immunol Res. 2013 Mar;55(1-3):58-70
pubmed: 22961658
Cancer Discov. 2021 Feb;11(2):384-407
pubmed: 33158843
Oncoimmunology. 2020 Jan 9;9(1):1703449
pubmed: 32002302
Cancer Immunol Immunother. 2015 Mar;64(3):337-47
pubmed: 25416072
J Clin Invest. 2019 Mar 1;129(3):1211-1228
pubmed: 30589644
Gynecol Oncol. 2019 May;153(2):217-222
pubmed: 30803719
Cancer Res. 2019 Jan 15;79(2):311-319
pubmed: 30482774
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Gynecol Oncol. 2019 Feb;152(2):243-250
pubmed: 30522700
Genes Chromosomes Cancer. 2011 Aug;50(8):606-18
pubmed: 21563232
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Front Oncol. 2015 Sep 22;5:202
pubmed: 26442214